Skip to main content
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc · Executive Compensation

Track KNSA — free
$93.90 +0.36 (+0.38%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$7.38B
Shares
78.57M
Volume · Nov 20 545.23K Avg daily vol (3M) 658.72K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Ross Moat Appointed 2026-10-22
Eben Tessari
“Mr. Tessari’s decision to resign was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices.”
Resigned 2026-05-01
Eben Tessari Appointed 2026-01-14
Ross Moat Appointed 2026-01-14
M. Cantey Boyd Appointed 2024-10-07
Eben Tessari Appointed 2022-01-03
Madelyn Zeylikman Appointed 2021-05-12
Mark Ragosa Appointed 2020-12-22

Leadership

Key facts CIK 1730430 CUSIP G52694109 13F (30d) 280 filings 272 filers Visit website Investor relations